Latest Breaking News On - தாக்கம் அடித்தளம் - Page 1 : comparemela.com

Lyndra Therapeutics Closes $60.5M Series C Financing Lyndra Therapeutics, a Watertown, Mass.-based clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, closed a $60.5m Series C financing. The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc. The company intends to use the funds to advance its lead product candidate into pivotal trials as they prepare for commercialization in the U.S., expand its central nervous system (CNS) pipeline assets and actively evaluate high value partnerships across a broad range of disease states.

United statesPatricia hurterAmy schulmanYipinhong pharmaceutical united statesAmerican international groupGilead sciences incImpact foundationLyndra therapeuticsYipinhong pharmaceuticalLimitless venturesCatalytic impact foundationPolaris partnersQuark ventureMass general brigham venturesGilead sciencesChief executive officer